Certara, Inc. (NASDAQ:CERT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Certara, Inc. (NASDAQ:CERT - Get Free Report) has received an average rating of "Moderate Buy" from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $15.67.

A number of analysts have weighed in on the stock. JMP Securities reaffirmed a "market perform" rating on shares of Certara in a research note on Tuesday, May 6th. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 price objective on the stock. Stephens reaffirmed an "overweight" rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and increased their target price for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. Finally, William Blair reissued a "market perform" rating on shares of Certara in a research note on Thursday, February 27th.

Certara Price Performance

Shares of CERT stock opened at $11.76 on Friday. The business has a fifty day simple moving average of $12.02 and a 200 day simple moving average of $11.83. The company has a market cap of $1.91 billion, a P/E ratio of -58.80, a P/E/G ratio of 9.29 and a beta of 1.44. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a twelve month low of $8.64 and a twelve month high of $17.22.

Certara (NASDAQ:CERT - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to analysts' expectations of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 earnings per share. On average, sell-side analysts forecast that Certara will post 0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ArrowMark Colorado Holdings LLC raised its stake in Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after buying an additional 3,861,674 shares during the period. Ameriprise Financial Inc. raised its position in shares of Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock valued at $40,253,000 after purchasing an additional 3,387,590 shares during the period. Mackenzie Financial Corp purchased a new position in shares of Certara in the fourth quarter valued at $17,852,000. Brown Brothers Harriman & Co. grew its stake in Certara by 63.8% during the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock valued at $40,668,000 after acquiring an additional 1,487,998 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Certara by 169.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company's stock valued at $21,248,000 after buying an additional 1,253,385 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.